Cilostazol increases patency and reduces adverse outcomes in percutaneous femoropopliteal revascularisation: a meta-analysis of randomised controlled trials

BACKGROUND: Cilostazol is an oral antiplatelet agent currently indicated for treatment of intermittent claudication. There is evidence that cilostazol may reduce femoropopliteal restenosis after percutaneous endovascular intervention. METHODS: We searched PubMed, Scopus and Cochrane databases from 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Benjo, Alexandre M, Garcia, Daniel C, Jenkins, J Stephen, Cardoso, Rhanderson M N, Molina, Taina P, El-Hayek, Georges E, Nadkarni, Girish N, Aziz, Emad F, Dinicolantonio, James J, Collins, Tyrone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225296/
https://www.ncbi.nlm.nih.gov/pubmed/25392738
http://dx.doi.org/10.1136/openhrt-2014-000154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225296/
https://www.ncbi.nlm.nih.gov/pubmed/25392738
http://dx.doi.org/10.1136/openhrt-2014-000154

Ejemplares similares